Brokers Set Expectations for Pharma-Bio Serv FY2026 Earnings

Pharma-Bio Serv Inc. (OTCMKTS:PBSV) – Zacks Research cut their FY2026 EPS estimates for shares of Pharma-Bio Serv in a research report issued on Tuesday, September 15th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings per share of $0.04 for the year, down from their previous estimate of $0.07. The consensus estimate for Pharma-Bio Serv’s current full-year earnings is $0.07 per share.

Pharma-Bio Serv Stock Down 25.9%

Shares of OTCMKTS:PBSV opened at $0.40 on Wednesday. The business’s 50 day moving average is $0.51 and its 200 day moving average is $0.52. The stock has a market cap of $9.16 million, a P/E ratio of 40.04 and a beta of 0.71. Pharma-Bio Serv has a 52-week low of $0.40 and a 52-week high of $1.36.

Pharma-Bio Serv (OTCMKTS:PBSV) last released its quarterly earnings results on Monday, June 15th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Pharma-Bio Serv had a return on equity of 2.32% and a net margin of 2.66%.The firm had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.70 million.

Pharma-Bio Serv Company Profile

Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc was founded in 1993 and is headquartered in Dorado, Puerto Rico.